Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.
Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.
Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.
Ginger Blackmon, PharmD, explains how NCODA’s Positive Quality Interventions (PQIs) help improve oncology care by guiding best practices, supporting teamwork, and streamlining workflows.
An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.
Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.
Research has even shown that cancer diagnosis can be significantly improved using AI, with real-time data updates, personalized attention, and ultimately better results at lower costs.
There is no single thing that can prevent all cancer risk, but there are 6 pillars of lifestyle that people can adopt to best prevent the disease.
